Elevation of a novel angiogenic factor, leucine-rich-α2-glycoprotein (LRG1), is associated with arterial stiffness, endothelial dysfunction, and peripheral arterial disease in patients with type 2 diabetes.

J Clin Endocrinol Metab

Clinical Research Unit (S.L.T.P., S.T., S.C.L., K.W., X.N., J.L.), Diabetes Centre (S.T., S.C.L., C.F.S.), and Division of Endocrinology (S.T., S.C.L., C.F.S.), Khoo Teck Puat Hospital, Singapore 768828; Metabolic Disease Research Programme (X.W.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 639798; Division of Nephrology (L.Y.Y.), Department of Medicine, Khoo Teck Puat Hospital, Singapore 768828; Institute of Molecular and Cell Biology (X.W.), A*STAR, Singapore 138673; and Institute of Ophthalmology (X.W.), University College London, London EC1V 9EL, United Kingdom.

Published: April 2015

AI Article Synopsis

  • Increased arterial stiffness and endothelial dysfunction are linked to peripheral arterial disease (PAD), with leucine-rich-α2-glycoprotein (LRG1) emerging as a crucial proangiogenic factor.
  • The study involved 2058 type 2 diabetes patients, revealing those with PAD had significantly higher LRG1 levels compared to those with normal or borderline ABI scores.
  • Factors such as gender, ethnicity, waist circumference, kidney function, and vascular health were significantly associated with elevated LRG1, indicating it could be a potential predictor for PAD risk alongside traditional factors.

Article Abstract

Context: Increased arterial stiffness and endothelial dysfunction are associated with peripheral arterial disease (PAD). Leucine-rich-α2-glycoprotein (LRG1) is a proangiogenic factor involved in regulation of the TGFβ signaling pathway.

Objective: This study in patients with type 2 diabetes mellitus explored the associations of plasma LRG1 with arterial stiffness, endothelial function, and PAD.

Design: Based on the ankle brachial index (ABI), patients were classified as having PAD (ABI ≤ 0.9) or as being borderline abnormal (ABI, 0.91-0.99) or normal (ABI, 1.00-1.40). LRG1 was measured by immunoassay; arterial stiffness, by carotid-femoral pulse-wave velocity and augmentation index; and endothelial function, by laser Doppler flowmetry.

Results: A total of 2058 patients with type 2 diabetes mellitus were recruited. Mean age (1 SD) was 57.4 (0.2) years. Patients with PAD (n = 258) had significantly higher LRG1 compared to patients with borderline ABI and patients without PAD (19.00 [13.50] vs 17.35 [13.30] and 15.28 [10.40] μg/mL, respectively; P < .0001). Multiple regression analysis revealed that female gender (P < .0001), non-Chinese ethnicity (P < .0001), higher waist circumference (P = .017), lower estimated glomerular filtration rate (P < .0001), higher urine albumin-creatinine ratio (P = .009), lower ABI (P < .0001), higher pulse wave velocity (P = .040), and poorer endothelium-dependent vasodilation (P = .007) were independent significant predictors of higher plasma LRG1 levels. A generalized linear model showed that a 1-SD increase in log LRG1 was associated with an odds ratio of 4.072 (95% confidence interval, 1.889-8.777; P < .0001) for prevalence of PAD, after adjustment for traditional risk factors.

Conclusions: Higher LRG1 is a significant predictor for arterial stiffness, endothelial function, and PAD. The pathobiological basis and the temporal relationships of these associations need to be explored by further mechanistic and prospective studies to understand the clinical significance of these findings.

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2014-3855DOI Listing

Publication Analysis

Top Keywords

arterial stiffness
20
stiffness endothelial
16
patients type
12
type diabetes
12
endothelial function
12
0001 higher
12
lrg1
8
leucine-rich-α2-glycoprotein lrg1
8
lrg1 associated
8
endothelial dysfunction
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!